The Diagnostic Value of Monocyte Chemoattractant Protein-1, Compared with Procalcitonin, C-reactive Protein, and Lactate in Bacteremia Estimation for Patients with Febrile Neutropenia

1. McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 2016;7(2):418-9. DOI: 10.3945/an.116.01221110.3945/an.116.012211478548526980827Search in Google Scholar

2. Ahmad AS, Ormiston-Smith N, Sasieni PD. Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960. Br J Cancer. 2015;112(5):943-7. DOI: 10.1038/bjc.2014.60610.1038/bjc.2014.606445394325647015Search in Google Scholar

3. Prat C, Sancho JM, Dominguez J, Xicoy B, Giménez M, Ferrà C, et al. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma. 2008;49(9):1752-61. DOI: 10.1080/1042819080225895610.1080/1042819080225895618661397Search in Google Scholar

4. Richter ME, Neugebauer S, Engelmann F, Hagel S, Ludewig K, La Rosée P, et al. Biomarker candidates for the detection of an infectious etiology of febrile neutropenia. Infection. 2016;44(2):175-86. DOI: 10.1007/s15010-015-0830-610.1007/s15010-015-0830-626275448Search in Google Scholar

5. Yang M, Choi SJ, Lee J, Lee DG, Kim YJ, Park YJ, et al. Serum procalcitonin as an independentdiagnostic markers of bacteremia in febrilepatients with hemato-logic malignancies. PLoS One. 2019;14(12):e0225765. DOI: 10.1371/journal.pone.022576510.1371/journal.pone.0225765690376331821331Search in Google Scholar

6. Secmeer G, Devrim I, Kara A, Ceyhan M, Cengiz B, Kutluk T, et al. Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia. J Pediatr Hematol Oncol 2007; 29: 107-11. DOI: 10.1097/MPH.0b013e3180320b5b10.1097/MPH.0b013e3180320b5b17279007Search in Google Scholar

7. Melgarejo E, Medina MÁ, Sánchez-Jiménez F, Urdiales JL. Monocyte chemoattractant protein-1: A key mediator in inflammatory processes. Int J Biochem Cell Biol 2009;41:998-1001. DOI: 10.1016/j.biocel.2008.07.01810.1016/j.biocel.2008.07.01818761421Search in Google Scholar

8. El-Maghraby SM, Moneer MM, Ismail MM, Shalaby LM, El-Mahallawy HA. The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies. J Pediatr Hematol Oncol. 2007;29(3):131-6. DOI: 10.1097/MPH.0b013e318030877010.1097/MPH.0b013e318030877017356388Search in Google Scholar

9. Neuenschwander LC, Bittencourt H, Ribeiro AFT, Teixeira AL, Teixeira MM, Teixeira JC, et al. Plasma levels of procalcitonin and eight additional inflammatory molecules in febrile neutropenic patients. Clinics (Sao Paulo). 2011;66(10):1699-705.Search in Google Scholar

10. Mato AR, Luger S, Loren AW, Heitjan DF, Olson ER, Ujjani C, et al. Serum lactic acid (LA) as a predictor of septic shock in patients with hematologic malignancies (HM) who develop febrile neutropenia. Blood. 2008;112(11):666. DOI: 10.1182/blood. V112.11.666.666Search in Google Scholar

11. Collins JM, Fleming GF, Christ TN. Comparison of the incidence of febrile neutropenia in obese and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastim. J Oncol Pharm Pract. 2019;25(5):1112-8. DOI: 10.1177/107815521877647110.1177/107815521877647129768957Search in Google Scholar

12. Işlak Mutcalı S, Saltoğlu N, Balkan İİ, Ozaras R, Yemişen M, Tabak F, et al. Early Changes of Man-nose-Binding Lectin, H-Ficolin, and Procalcitonin in Patients with Febrile Neutropenia: A Prospective Observational Study. Turk J Haematol. 2016;33(4):304-10. DOI: 10.4274/tjh.2014.038510.4274/tjh.2014.0385520418526377840Search in Google Scholar

13. Lubwama M, Phipps W, Najjuka CF, Kajumbula H, Ddungu H, Kambugu H, et al. Bacteremia in febrile cancer patients in Uganda. BMC Res Notes. 2019;12(1):464. DOI: 10.1186/s13104-019-4520-910.1186/s13104-019-4520-9666818131362783Search in Google Scholar

14. Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(5):111-8. DOI: 10.1093/annonc/mdw32510.1093/annonc/mdw32527664247Search in Google Scholar

15. Carvalho AS, Lagana D, Catford J, Shaw D, Bak N. Bloodstream infections in neutropenic patients with haematological malignancies. Infect Dis & Health. 2020;25(1):22-9. DOI: 10.1016/j.idh.2019.08.00610.1016/j.idh.2019.08.00631586572Search in Google Scholar

16. Michel CS, Teschner D, Wagner EM, Theobald M, Radsak MP. Diagnostic value of sTREM-1, IL-8, PCT, and CRP in febrile neutropenia after autologous stem cell transplantation. Ann Hematol. 2017;96(12):2095-101. DOI: 10.1007/s00277-017-3128-110.1007/s00277-017-3128-128920169Search in Google Scholar

17. Lima SSS, Nobre V, de Castro Romanelli RM, Clemente WT, Da Silva Bittencourt HN, Melo ACM, et al. Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Ann Hematol. 2016;95(7):1169-76. DOI: 10.1007/s00277-016-2639-510.1007/s00277-016-2639-527118539Search in Google Scholar

18. García de Guadiana-Romualdo L, Espa-ol-Morales I, Cerezuela-Fuentes P, Consuegra-Sánchez L, Hernando-Holgado A, Esteban-Torrella P, et al. Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6. Support Care Cancer. 2015;23(7):2175-82. DOI: 10.1007/s00520-014-2589-110.1007/s00520-014-2589-125564222Search in Google Scholar